Literature DB >> 12226839

Alkaline hydrolysis of oxaliplatin--isolation and identification of the oxalato monodentate intermediate.

Elin Jerremalm1, Pernilla Videhult, Gunvor Alvelius, William J Griffiths, Tomas Bergman, Staffan Eksborg, Hans Ehrsson.   

Abstract

The alkaline degradation of the chemotherapeutic agent oxaliplatin has been studied using liquid chromatography. The oxalato ligand is lost in two consecutive steps. First, the oxalato ring is opened, forming an oxalato monodentate intermediate, as identified by electrospray ionization mass spectrometry. Subsequently, the oxalato ligand is lost and the dihydrated oxaliplatin complex is formed. The observed rate constants for the first step (k(1)) and the second step (k(2)) follow the equation k(1) or k(2) = k(0) + k(OH(-) )[OH(-)], where k(0) is the rate constant for the degradation catalyzed by water and k(OH(-) ) represents the second-order rate constant for the degradation catalyzed by the hydroxide ion. At 37 degrees C the rate constants for the first step are k(OH(-) ) = 5.5 x 10(-2) min(-1) M(-1) [95% confidence interval (CI), 2.7 x 10(-2) to 8.4 x 10(-2) min(-1) M(-1)] and k(0) = 4.3 x 10(-2) min(-1) (95% CI, 4.0 x 10(-2) to 4.7 x 10(-2) min(-1)). For the second step the rate constants are k(OH(-) ) = 1.1 x 10(-3) min(-1) M(-1) (95% CI, -1.1 x 10(-3) to 3.3 x 10(-3)) min(-1) M(-1) and k(0) = 7.5 x 10(-3) min(-1) (95% CI, 7.2 x 10(-3) to 7.8 x 10(-3) min(-1)). Thus, the ring-opening step is nearly six times faster than the step involving the loss of the oxalato ligand. Copyright 2002 Wiley-Liss Inc. and the American Pharmaceutical Association

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12226839     DOI: 10.1002/jps.10201

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

Review 1.  Third row transition metals for the treatment of cancer.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2015-03-13       Impact factor: 4.226

Review 2.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

3.  Towards Antitumor Active trans-Platinum Compounds.

Authors:  Sheena M Aris; Nicholas P Farrell
Journal:  Eur J Inorg Chem       Date:  2009-04-01       Impact factor: 2.524

4.  Platinum (II) complex-nuclear localization sequence peptide hybrid for overcoming platinum resistance in cancer therapy.

Authors:  Marek T Wlodarczyk; Sylwia A Dragulska; Olga Camacho-Vanegas; Peter R Dottino; Andrzej A Jarzęcki; John A Martignetti; Aneta J Mieszawska
Journal:  ACS Biomater Sci Eng       Date:  2018-01-09

5.  A Dogma in Doubt: Hydrolysis of Equatorial Ligands of PtIV Complexes under Physiological Conditions.

Authors:  Alexander Kastner; Isabella Poetsch; Josef Mayr; Jaroslav V Burda; Alexander Roller; Petra Heffeter; Bernhard K Keppler; Christian R Kowol
Journal:  Angew Chem Int Ed Engl       Date:  2019-04-25       Impact factor: 15.336

6.  The hybrid models, containing hydrolytic and electron-driven processes, in theoretical study of oxaliplatin biotransformation.

Authors:  Janina Kuduk-Jaworska; Jerzy J Jański; Szczepan Roszak
Journal:  J Mol Model       Date:  2020-09-26       Impact factor: 1.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.